Insider Buying: Kodiak Sciences (NASDAQ:KOD) Director Buys $2,868,396.30 in Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker bought 33,726 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The stock was bought at an average cost of $85.05 per share, for a total transaction of $2,868,396.30. Following the completion of the transaction, the director directly owned 20,191,214 shares of the company’s stock, valued at approximately $1,717,262,750.70. The trade was a 0.17% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, September 28th, Bros. Advisors Lp Baker purchased 807,840 shares of Kodiak Sciences stock. The shares were bought at an average cost of $72.57 per share, with a total value of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 418,323 shares of Kodiak Sciences stock. The shares were bought at an average cost of $83.58 per share, for a total transaction of $34,963,436.34.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 681,866 shares of Kodiak Sciences stock. The stock was bought at an average price of $88.77 per share, for a total transaction of $60,529,244.82.

Kodiak Sciences Stock Down 4.1%

KOD stock opened at $94.45 on Friday. The business has a fifty day simple moving average of $43.53 and a 200-day simple moving average of $39.69. The company has a market cap of $5.94 billion, a price-to-earnings ratio of -22.54 and a beta of 2.03. Kodiak Sciences Inc. has a 52 week low of $10.94 and a 52 week high of $104.00.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). As a group, analysts expect that Kodiak Sciences Inc. will post -3.97 earnings per share for the current fiscal year.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Positive Phase 3 results remain the primary catalyst. Kodiak’s Zenkuda/KSI-501 reportedly met key goals in the DAYBREAK trial for wet age-related macular degeneration, outperforming or matching Eylea on important endpoints. The results support plans to pursue a biologics license application and strengthen the company’s potential position in the large retinal-disease market. Kodiak Sciences more than doubles on eye disease trial results
• Positive Sentiment: Analyst price targets have moved higher. Kodiak’s consensus target reportedly increased 65.16% to $117.50. Jefferies maintains a Buy rating with a $112 target, while HC Wainwright raised its target to $96 and lifted longer-term earnings estimates based on the trial opportunity. Kodiak Sciences consensus price target increased
• Positive Sentiment: Insider buying provides an additional confidence signal. Director Bros. Advisors LP Baker purchased 33,726 shares at about $85.05, following several larger purchases totaling roughly 1.94 million shares in late September. Kodiak Sciences insider purchase
• Neutral Sentiment: Expectations for future earnings are being reset. Brokers are forecasting continued losses in the near term, but the potential commercial impact of Zenkuda has led to substantially improved FY2027-and-beyond estimates. Kodiak Sciences FY2027 earnings expectations
• Negative Sentiment: The stock’s rapid advance raises near-term correction risk. Shares have climbed from roughly $37 to above $100 in about a month and have delivered a gain of more than 500% over the past year. Such momentum can encourage profit-taking, while Kodiak remains an unprofitable biotechnology company with execution, regulatory and financing risks. Kodiak Sciences comeback and dealmaking

Institutional Trading of Kodiak Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE bought a new position in shares of Kodiak Sciences during the 2nd quarter valued at about $14,949,000. Algert Global LLC raised its stake in Kodiak Sciences by 26.1% during the 2nd quarter. Algert Global LLC now owns 186,476 shares of the company’s stock valued at $7,265,000 after purchasing an additional 38,546 shares during the period. GSA Capital Partners LLP acquired a new position in Kodiak Sciences during the second quarter valued at $1,072,000. The Manufacturers Life Insurance Company increased its holdings in shares of Kodiak Sciences by 31.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company’s stock valued at $4,598,000 after purchasing an additional 29,121 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Kodiak Sciences in the 2nd quarter worth approximately $4,361,000. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KOD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Jefferies Financial Group reiterated a “buy” rating and issued a $112.00 price target on shares of Kodiak Sciences in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $103.00 target price on shares of Kodiak Sciences in a research note on Wednesday. Finally, UBS Group lifted their price target on Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a report on Monday, September 28th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kodiak Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $100.43.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.